Characterization of acute and chronic neuropathies induced by oxaliplatin in mice and differential effects of a novel mitochondria-targeted antioxidant on the neuropathies

Anesthesiology

Volumn 120, Issue 2, 2014, Pages 459-473

  Toyama, Satoshi ^a   Shimoyama, Naohito ^a,b   Ishida, Yasuo ^a   Koyasu, Takayoshi ^a   Szeto, Hazel H ^c   Shimoyama, Megumi ^a  

^a TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^b JIKEI UNIVERSITY HOSPITAL   (Japan)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CELL LINE, TUMOR; CHRONIC DISEASE; COLD TEMPERATURE; GANGLIA, SPINAL; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, SCID; MITOCHONDRIA; NEOPLASM TRANSPLANTATION; ORGANOPLATINUM COMPOUNDS; PAIN MEASUREMENT; PAIN THRESHOLD; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSICAL STIMULATION; POSTERIOR HORN CELLS; PROTO-ONCOGENE PROTEINS C-FOS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES;

EID: 84895063161     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/01.anes.0000435634.34709.65     Document Type: Article

References (68)

1. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A; Multicenter International Study of Oxaliplatin/5-Fluorouracil/ Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-51
2. Baker DE: Oxaliplatin: A new drug for the treatment of metastatic carcinoma of the colon or rectum. Rev Gastroenterol Disord 2003; 3:31-8
3. Attal N, Bouhassira D, Gautron M, Vaillant JN, Mitry E, Lepère C, Rougier P, Guirimand F: Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: A prospective quantified sensory assessment study. Pain 2009; 144:245-52
4. Binder A, Stengel M, Maag R, Wasner G, Schoch R, Moosig F, Schommer B, Baron R: Pain in oxaliplatin-induced neuropathy-Sensitisation in the peripheral and central nociceptive system. Eur J Cancer 2007; 43:2658-63
5. de Gramont A: Rapid evolution in colorectal cancer: Therapy now and over the next five years. Oncologist 2005; 10(suppl 2):4-8
6. Leonard GD, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B, Thomas RR, Grem JL: Survey of oxaliplatin-Associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 2005; 5:116
7. Pasetto LM, D'Andrea MR, Rossi E, Monfardini S: Oxaliplatinrelated neurotoxicity: How and why? Crit Rev Oncol Hematol 2006; 59:159-68
8. Saif MW, Reardon J: Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 2005; 1:249-58
9. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MG, Grem JL: Acute oxaliplatin-induced peripheral nerve excitability. J Clin Oncol 2002; 20:1767-74
10. Raymond E, Chaney SG, Taamma A, Cvitkovic E: Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 1998; 9:1053-71
11. Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25:299-303
12. Cavaletti G, Tredici G, Petruccioli MG, Dondè E, Tredici P, Marmiroli P, Minoia C, Ronchi A, Bayssas M, Etienne GG: Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 2001; 37:2457-63
13. Donzelli E, Carfì M, Miloso M, Strada A, Galbiati S, Bayssas M, Griffon-Etienne G, Cavaletti G, Petruccioli MG, Tredici G: Neurotoxicity of platinum compounds: Comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y. J Neurooncol 2004; 67:65-73
14. McKeage MJ, Hsu T, Screnci D, Haddad G, Baguley BC: Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer 2001; 85:1219-25
15. Ta LE, Espeset L, Podratz J, Windebank AJ: Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 2006; 27:992-1002
16. Jamieson SM, Liu J, Connor B, McKeage MJ: Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother Pharmacol 2005; 56:391-9
17. Renn CL, Carozzi VA, Rhee P, Gallop D, Dorsey SG, Cavaletti G: Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice. Mol Pain 2011; 7:29
18. Xiao WH, Zheng H, Bennett GJ: Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience 2012; 203:194-206
19. Banerjee S, Kong D, Azmi AS, Wang Z, Ahmad A, Sethi S, Sarkar FH: Restoring sensitivity to oxaliplatin by a novel approach in gemcitabine- resistant pancreatic cancer cells in vitro and in vivo. Int J Cancer 2011; 128:1240-50
20. Cividalli A, Ceciarelli F, Livdi E, Altavista P, Cruciani G, Marchetti P, Danesi DT: Radiosensitization by oxaliplatin in a mouse adenocarcinoma: Influence of treatment schedule. Int J Radiat Oncol Biol Phys 2002; 52:1092-8
21. Xiong W, Ren ZG, Qiu SJ, Sun HC, Wang L, Liu BB, Li QS, Zhang W, Zhu XD, Liu L, Wang WQ, Tang ZY: Residual hepatocellular carcinoma after oxaliplatin treatment has increased metastatic potential in a nude mouse model and is attenuated by Songyou Yin. BMC Cancer 2010; 10:219
22. Di Cesare Mannelli L, Zanardelli M, Failli P, Ghelardini C: Oxaliplatin-induced neuropathy: Oxidative stress as pathological mechanism. Protective effect of silibinin. J Pain 2012; 13:276-84
23. Joseph EK, Chen X, Bogen O, Levine JD: Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stressdependent acute painful peripheral neuropathy. J Pain 2008; 9:463-72
24. Xiao WH, Bennett GJ: Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents, paclitaxel and oxaliplatin. Pain 2012; 153:704-9
25. Zheng H, Xiao WH, Bennett GJ: Functional deficits in peripheral nerve mitochondria in rats with paclitaxel-And oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol 2011; 232:154-61
26. Zhao K, Luo G, Giannelli S, Szeto HH: Mitochondria-Targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines. Biochem Pharmacol 2005; 70:1796-806
27. Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW, Szeto HH: Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem 2004; 279:34682-90
28. Calkins MJ, Manczak M, Mao P, Shirendeb U, Reddy PH: Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Hum Mol Genet 2011; 20:4515-29
29. Calkins MJ, Manczak M, Reddy PH: Mitochondria-Targeted antioxidant SS31 prevents amyloid beta-induced mitochondrial abnormalities and synaptic degeneration in Alzheimer's disease. Pharmaceuticals (Basel) 2012; 5:1103-19
30. Cho S, Szeto HH, Kim E, Kim H, Tolhurst AT, Pinto JT: A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. J Biol Chem 2007; 282:4634-42
31. Manczak M, Mao P, Calkins MJ, Cornea A, Reddy AP, Murphy MP, Szeto HH, Park B, Reddy PH: Mitochondria-Targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J Alzheimers Dis 2010; 20(suppl 2):S609-31
32. Petri S, Kiaei M, Damiano M, Hiller A, Wille E, Manfredi G, Calingasan NY, Szeto HH, Beal MF: Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J Neurochem 2006; 98:1141-8
33. Reddy TP, Manczak M, Calkins MJ, Mao P, Reddy AP, Shirendeb U, Park B, Reddy PH: Toxicity of neurons treated with herbicides and neuroprotection by mitochondria-Targeted antioxidant SS31. Int J Environ Res Public Health 2011; 8:203-21
34. Yang L, Zhao K, Calingasan NY, Luo G, Szeto HH, Beal MF: Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-Tetrahydropyridine neurotoxicity. Antioxid Redox Signal 2009; 11:2095-104
35. Zimmermann M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983; 16:109-10
36. Walczak JS, Beaulieu P: Comparison of three models of neuropathic pain in mice using a new method to assess cold allodynia: The double plate technique. Neurosci Lett 2006; 399:240-4
37. Beecher HK: The measurement of pain; prototype for the quantitative study of subjective responses. Pharmacol Rev 1957; 9:59-209
38. Knowlton WM, Bifolck-Fisher A, Bautista DM, McKemy DD: TRPM8, but not TRPA1, is required for neural and behavioral responses to acute noxious cold temperatures and coldmimetics in vivo. Pain 2010; 150:340-50
39. Coggeshall RE: Fos, nociception and the dorsal horn. Prog Neurobiol 2005; 77:299-352
40. Shimoyama M, Tatsuoka H, Ohtori S, Tanaka K, Shimoyama N: Change of dorsal horn neurochemistry in a mouse model of neuropathic cancer pain. Pain 2005; 114:221-30
41. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994; 53:55-63
42. Allchorne AJ, Broom DC, Woolf CJ: Detection of cold pain, cold allodynia and cold hyperalgesia in freely behaving rats. Mol Pain 2005; 1:36
43. Jordt SE, Bautista DM, Chuang HH, McKemy DD, Zygmunt PM, Högestätt ED, Meng ID, Julius D: Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 2004; 427:260-5
44. Story GM, Peier AM, Reeve AJ, Eid SR, Mosbacher J, Hricik TR, Earley TJ, Hergarden AC, Andersson DA, Hwang SW, McIntyre P, Jegla T, Bevan S, Patapoutian A: ANKTM1, a TRPlike channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 2003; 112:819-29
45. Mogil JS, Crager SE: What should we be measuring in behavioral studies of chronic pain in animals? Pain 2004; 112:12-5
46. Catheline G, Le Guen S, Honoré P, Besson JM: Are there longterm changes in the basal or evoked Fos expression in the dorsal horn of the spinal cord of the mononeuropathic rat? Pain 1999; 80:347-57
47. Burakgazi AZ, Messersmith W, Vaidya D, Hauer P, Hoke A, Polydefkis M: Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology 2011; 77:980-6
48. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC: Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 2005; 32:51-60
49. Pietrangeli A, Leandri M, Terzoli E, Jandolo B, Garufi C: Persistence of high-dose oxaliplatin-induced neuropathy at long-Term follow-up. Eur Neurol 2006; 56:13-6
50. Descoeur J, Pereira V, Pizzoccaro A, Francois A, Ling B, Maffre V, Couette B, Busserolles J, Courteix C, Noel J, Lazdunski M, Eschalier A, Authier N, Bourinet E: Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. EMBO Mol Med 2011; 3:266-78
51. Joseph EK, Levine JD: Comparison of oxaliplatin-And cisplatin-induced painful peripheral neuropathy in the rat. J Pain 2009; 10:534-41
52. Ling B, Authier N, Balayssac D, Eschalier A, Coudore F: Behavioral and pharmacological description of oxaliplatininduced painful neuropathy in rat. Pain 2007; 128:225-34
53. Ling B, Coudoré-Civiale MA, Balayssac D, Eschalier A, Coudoré F, Authier N: Behavioral and immunohistological assessment of painful neuropathy induced by a single oxaliplatin injection in the rat. Toxicology 2007; 234:176-84
54. Nassini R, Gees M, Harrison S, De Siena G, Materazzi S, Moretto N, Failli P, Preti D, Marchetti N, Cavazzini A, Mancini F, Pedretti P, Nilius B, Patacchini R, Geppetti P: Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. Pain 2011; 152:1621-31
55. Sakurai M, Egashira N, Kawashiri T, Yano T, Ikesue H, Oishi R: Oxaliplatin-induced neuropathy in the rat: Involvement of oxalate in cold hyperalgesia but not mechanical allodynia. Pain 2009; 147:165-74
56. Ta LE, Low PA, Windebank AJ: Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli. Mol Pain 2009; 5:9
57. Boyette-Davis J, Dougherty PM: Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline. Exp Neurol 2011; 229:353-7
58. Flatters SJ, Bennett GJ: Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: Evidence for mitochondrial dysfunction. Pain 2006; 122:245-57
59. Kim HK, Zhang YP, Gwak YS, Abdi S: Phenyl N-Tertbutylnitrone, a free radical scavenger, reduces mechanical allodynia in chemotherapy-induced neuropathic pain in rats. Anesthesiology 2010; 112:432-9
60. Anand U, Otto WR, Anand P: Sensitization of capsaicin and icilin responses in oxaliplatin treated adult rat DRG neurons. Mol Pain 2010; 6:82
61. Gauchan P, Andoh T, Kato A, Kuraishi Y: Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice. Neurosci Lett 2009; 458:93-5
62. Kawashiri T, Egashira N, Kurobe K, Tsutsumi K, Yamashita Y, Ushio S, Yano T, Oishi R: L type Ca++ channel blockers prevent oxaliplatin-induced cold hyperalgesia and TRPM8 overexpression in rats. Mol Pain 2012; 8:7
63. Zhao M, Isami K, Nakamura S, Shirakawa H, Nakagawa T, Kaneko S: Acute cold hypersensitivity characteristically induced by oxaliplatin is caused by the enhanced responsiveness of TRPA1 in mice. Mol Pain 2012; 8:55
64. Webster RG, Brain KL, Wilson RH, Grem JL, Vincent A: Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltagegated sodium channels. Br J Pharmacol 2005; 146:1027-39
65. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C: The chemotherapeutic oxaliplatin alters voltagegated Na+ channel kinetics on rat sensory neurons. Eur J Pharmacol 2000; 406:25-32
66. Benoit E, Brienza S, Dubois JM: Oxaliplatin, an anticancer agent that affects both Na+ and K+ channels in frog peripheral myelinated axons. Gen Physiol Biophys 2006; 25:263-76
67. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E: A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001; 85:2293-7
68. Kagiava A, Tsingotjidou A, Emmanouilides C, Theophilidis G: The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. Neurotoxicology 2008; 29:1100-6